LYVE1 and neoplasm: Besides, IHC staining of lymphatic endothelial-specific antibody LYVE-1 suggested that tumor-associated lymphangiogenesis correlated with increased nodal spread and higher recurrence risk (Supplementary Fig. S2F–I), suggesting that approaches targeting lymphangiogenesis could have therapeutic potency in ICC.